Superficial Bladder Cancer Clinical Trial
Official title:
A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients Who Are BCG Naïve or Received Incomplete BCG Treatment
This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establish safety and recommended the phase 2 dose, followed by a Phase 2 study to establish how effective the treatment is. The Study will include patients with NMIBC with Cis for whom BCG therapy is unresponsive and patients with NMIBC with Cis who are BCG-naïve or inadequately treated.
EG-70 is a novel non-viral gene therapy. EG-70 is designed to elicit a local immune response following delivery of the study gene therapy to the bladder urothelium. This approach of local administration through bladder instillation has the potential to induce a potent immune response exclusively at the site of the tumor, resulting in greater therapeutic benefit while reducing undesirable systemic toxicity. Eligible BCG-unresponsive NMIBC patients will be enrolled in Phase 1, and Cohort 1 of Phase 2. Eligible high-risk NMIBC patients who have been incompletely treated or are BCG-naïve will be enrolled starting in Phase 2 in a separate single-arm cohort (Cohort 2). Patients will be treated for up to four 12-week cycles of study drug instillation doses and assessments with follow up assessments. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01687244 -
Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer
|
Phase 2 | |
Completed |
NCT02773849 -
ADSTILADRIN (=INSTILADRIN) in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
|
Phase 3 | |
Recruiting |
NCT03379909 -
Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer
|
Phase 2 | |
Completed |
NCT00782587 -
Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer
|
Phase 1 | |
Recruiting |
NCT05084586 -
Comparison of the Efficacy and Safety of Continuous and Single-Dose Intravesical Epirubicin Instillation
|
N/A | |
Recruiting |
NCT03121768 -
A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
|
N/A | |
Completed |
NCT03091764 -
Evaluation of a Patient-Reported Symptom Index for NMIBC
|
||
Completed |
NCT01939756 -
Intravesical Natural Baobab Oil in the Management of BCG-induced Lower Urinary Tract Symptoms
|
Phase 1/Phase 2 | |
Completed |
NCT00595088 -
Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer
|
Phase 2 | |
Completed |
NCT02007005 -
Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01149174 -
Preoperative Intravesical Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer
|
Phase 3 | |
Completed |
NCT00322699 -
Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00191711 -
Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk.
|
Phase 2 | |
Completed |
NCT00192049 -
A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer
|
Phase 2 | |
Recruiting |
NCT02106572 -
Therapeutic Instillation of Mistletoe
|
Phase 3 | |
Completed |
NCT00734994 -
Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer
|
Phase 0 |